...I think it'll be a moot point. as I expect AMPE to strike some form of deal with Big Pharma in the first half of 2014, and the stock price will soar. I believe that there are numerous Big Pharma companies looking to do a deal with AMPE to gain control of Ampion. The obvious question is what they are willing to pay, and how the deal will be structured - outright buyout or partnership.
.... in the world of Biotech investing, it's easy to bash and be negative simply because most Biotech drugs fail to get FDA approval, and quite a few Biotech companies fail. But "The Perp's" missives on Ampion have been truely slanted and grossly biased. Ampion is a drug that has a very high probability of gaining FDA approval, and will positively impact the lives of millions of Americans who suffer from Ostheoarthritis of the knee, which is reaching epidemic proportions as Baby Boomers age. Yet the "The Perp" cherry picks information to falsely paint a negative picture of Ampion. He is truely a propagandist, not a journalist. I call him "The Perp" because he deserves to be locked up behind bars.
...in regards to AMPE, he has ZERO credibility. Zertane is a meaningless sideshow compared to Ampion, which will be approved in 2014 or 2015 and become a blockbuster.
Oh Ampiooooh, you stupid worm. You're like a bad rash that won't go away. Speak to me a year from now, you moron, and we'll see who's making the big money. #$%$.
...stock action past month is very tough to take, but what is undeniable is the clinical data for Ampion and how quickly the drug is progressing to market. At some point in 2014, AMPE will announce some form of deal with Big Pharma. That is inevitable. The Ostheoarthritis market is HUGE, and the only question is whether AMPE will have a 1, 2 or 3 Billion market cap in time.
....Breakthrough Therapy or Accelerated Approval designation. The FDA will rule on AMPE's application by sometime in January. If AMPE is granted either, the stock should take off, as it is essentially an FDA blessing of Ampion. If such occurs, it will finally blow all the shorts out of the water, and allow AMPE to negotiate from strength with Big Pharma for some form of partnership.
.....Ampe is the short's #$%$.
...for such an abject failure to properly get the story across to institutions. Hence you have great execution by AMPE with it's business plan but a stock price that reflects none of it.
A couple of thoughts - agreed that Macaluso may not have the expertise, sophistication or experience to take AMPE to the next level. However, if the FDA awards them a Breakthrough Therapy or Accelerated Approval designation in the coming month, that will take all the salesmanship out of Macaluso's hands, as the designation will loudly speak for itself. Thereafter it's simply the matter of striking a strong partnership deal with Big Pharma.
Tremendous post. Macaluso is enthusiastic and well intentioned, but the failure of the stock to reflect it's true value is the fault of management.
...agreed. Getting dominated by the Shorts. A failure by Management to get more Institutions/Funds involved with the stock. Sad.
...well said. This has been my biggest worry - that someone would try to take them over on the cheap. The company should have a poison pill, but probably is hesitant to do so in fear of #$%$ off shareholders. That they will succeed is not a worry - a hostile takeover is.
FDA guidance for final Phase 3 trial is past 30 day period - the 29th - so decision is due any day. Breakthrough or accelerated approval decision is due within 60 days of application, which is separate from the Pre-BLA meeting on 10/29. My understanding is application was recently submitted, so decision due by end of January or before, as FDA has 60 days to respond. I think accelerated approval has a good chance of being granted, which would be VERY GOOD for shareholders.
...which is just so pathetic. His personal, twisted vendetta against AMPE has gone so far that he posts on the Yahoo Message Board as Ampiooooh. "The Perp" is not a journalist, he is more like a propagandist of the worst sort.